Immunohematology最新文献

{"title":"BOOK REVIEW: Methods in Immunohematology","authors":"R. Mougey","doi":"10.21307/immunohematology-2019-1113","DOIUrl":"https://doi.org/10.21307/immunohematology-2019-1113","url":null,"abstract":"","PeriodicalId":13357,"journal":{"name":"Immunohematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47803835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comment on \"Reagents for the 1990's\".","authors":"D. Mallory","doi":"10.21307/IMMUNOHEMATOLOGY-2019-1019","DOIUrl":"https://doi.org/10.21307/IMMUNOHEMATOLOGY-2019-1019","url":null,"abstract":"","PeriodicalId":13357,"journal":{"name":"Immunohematology","volume":"7 3 1","pages":"82"},"PeriodicalIF":0.0,"publicationDate":"2020-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45283178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter from the Editor: Abbott Dedication","authors":"D. Mallory","doi":"10.21307/IMMUNOHEMATOLOGY-2019-1028","DOIUrl":"https://doi.org/10.21307/IMMUNOHEMATOLOGY-2019-1028","url":null,"abstract":"","PeriodicalId":13357,"journal":{"name":"Immunohematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45395904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concordance of two polymerase chain reaction-based blood group genotyping platforms for patients with sickle cell disease.","authors":"Chelsea A Sheppard,&nbsp;Nicole L Bolen,&nbsp;Geralyn Meny,&nbsp;Monica Kalvelage,&nbsp;Gorka Ochoa-Garay","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Conclusions: </strong>In recent years, polymerase chain reaction-based genotyping platforms, which provide a predicted phenotype, have increased in both patient and high-throughput donor testing, especially in situations where serologic methods or reagents are limited. This study looks at the concordance rate between two platforms commercially available in the United States when used for testing samples from patients with sickle cell disease (SCD), a group particularly vulnerable to alloimmunization. DNA extracted from samples from 138 patients with SCD was tested by human erythrocyte antigen (HEA) BeadChip (Immucor, Norcross, GA) and by ID CORE XT (Progenika-Grifols, Barcelona, Spain). Predicted phenotype results were compared, and a concordance rate was calculated. Discrepancies were resolved by Sanger sequencing. All testing was done under an institutional review board-approved protocol. A concordance rate of 99.9 percent was obtained. Sanger sequencing was performed on four samples with discrepancies in the Rh blood group system. Three samples had a similar allelic variant detected by ID CORE XT. Two of the three discrepant samples were correctly identified as V+w, VS- by ID CORE XT but not by HEA BeadChip. The third sample, predicted to have a phenotype of V+, VS+ by sequencing, was called correctly by HEA BeadChip but not by ID CORE XT, which had predicted V+w, VS-. The fourth discrepancy was identified in a sample that ID CORE XT accurately identified as RHCE*ce[712G] and predicted a partial c phenotype. This result was confirmed by Sanger sequencing, whereas HEA BeadChip found no variants and predicted a c+ phenotype. The high concordance rate of the two methods, along with the known limitations of serology, warrant further discussion regarding the practice of serologic confirmation of extended phenotypes. Clinical significance of the identified discrepancies remains to be determined.</p>","PeriodicalId":13357,"journal":{"name":"Immunohematology","volume":"36 4","pages":"123-128"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25335052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical impacts of DNA-based typing and provision of antigen-matched red blood cell units for chronically transfused patients with thalassemia.","authors":"Phandee Watanaboonyongcharoen,&nbsp;Sunisa Onspun,&nbsp;Ponlapat Rojnuckarin","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Conclusions: </strong>Blood transfusion, the main therapy for patients with severe thalassemia, is challenged by alloantibodies that can lead to hemolytic transfusion reactions. The use of prophylactic antigen-matched units is recommended, but serologic typing, before the first transfusion, is rarely performed and is not reliable after chronic transfusion. Patient DNA-based typing is a promising strategy, but clinical outcome data are lacking. The aim of this study was to determine the benefits of antigenmatched transfusion guided by DNA-based typing in terms of new alloantibody formation and increases in mean pretransfusion hemoglobin (Hb) levels. We performed DNA-based typing on samples from 24 transfusion-dependent patients with thalassemia who had no serologic phenotyping performed before the first transfusion. These patients were then transfused with antigen-matched donor RBC units that were typed serologically. New alloantibody formation and mean pre-transfusion Hb levels were evaluated after implementing this extended common antigen-matching transfusion protocol. Sixty-three percent of the patients in this study were diagnosed as having beta-thalassemia Hb E. Alloantibodies were already present in 87.5 percent (21/24) of these patients, and most of these antibodies were multiple and/ or unidentified. After the enrollment, there were 717 transfusion episodes comprising 1209 RBC units. The number of RBC units transfused to each patient ranged from 22 to 119 units. At the median duration of 25.5 months (range 10-34 months), no new alloantibodies were detected since the beginning of the protocol. Seventy-four transfusion episodes in six patients were crossmatch-positive due to autoantibodies (patients 2, 4, 8, 9, and 14) or anti-Chido (patient 18) that had been identified before the study. There were no hemolytic transfusion reactions in this study. Five patients (patients 1, 2, 12, 15, and 20) showed increased mean pre-transfusion Hb levels (≥1 g/dL) and one patient (patient 16) had longer intervals between transfusions (compared with those before the protocol), suggesting longer RBC survival, although there was no statistical difference in the whole group. Our study highlights the benefits of DNA-based typing in chronically transfused patients with thalassemia who had no phenotyping data before the first transfusion. Patient DNA-based typing for antigen-matched transfusion is safe in thalassemia and allows us to obtain better-matched blood units for complicated patients.</p>","PeriodicalId":13357,"journal":{"name":"Immunohematology","volume":"36 4","pages":"137-145"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25335055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of DEL phenotype in D- blood donors in India.","authors":"Rajendra Chaudhary,&nbsp;Sunil Verma,&nbsp;Anupam Verma","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Conclusions: </strong>Unlike weak D and partial D, DEL represents a weakened form of D that cannot be detected by conventional serology and requires use of an adsorption-elution method for its detection; therefore, DEL+ samples might be mistyped as D-. The study was undertaken to determine the prevalence of the DEL phenotype among D- blood donors from northern India. A total of 1003 D- blood donors were tested for weak D and DEL by the indirect antiglobulin test and an adsorption-elution method, respectively. Of the total 21,135 blood donors typed for D, 20,132 (95.3%) were D+ and 1003 (4.7%) gave a negative reaction for D. Of the total 1003 D- samples, 8 (0.8%) were weak D and only 2 (0.2%) were DEL+ by adsorption-elution testing. For samples that typed as D-, the majority of individuals (91.1%) were cde/cde (rr) followed by dCe/dce (r´r) in 4.8 percent, and dCe/dCe (r´r´) in 2.2 percent. Both DEL+ samples were also C+. We conclude that the prevalence of the DEL phenotype as detected by serology in D- north Indian blood donors is 0.2 percent, although it is as high as 2.8 percent in D-C+ individuals. There is an association of DEL with C, which can be used as a cost-effective marker for screening large numbers of D- blood donors for DEL.</p>","PeriodicalId":13357,"journal":{"name":"Immunohematology","volume":"36 4","pages":"133-136"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25335054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying obstetrics patients in whom RHD genotyping can be used to assess risk of D alloimmunization.","authors":"Trina N Horn,&nbsp;Jessica Keller,&nbsp;Margaret A Keller,&nbsp;Liz Klinger","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Conclusions: </strong>The D antigen is highly immunogenic and may cause alloimmunization to occur after blood transfusion or pregnancy. Some RHD variant alleles express a D antigen that is missing one or more epitopes, thus putting a presumed D+ patient at risk for alloanti-D and hemolytic disease of the fetus and newborn. It is generally accepted that individuals who have a serologic weak D phenotype due to one of three alleles common in Caucasians, RHD*weak D types 1, 2, or 3, are not at risk for alloimmunization. In this study, blood samples from 46 obstetrics patients from a local health system were identified based on discrepant results between automated gel and manual tube testing (n = 20) or based on presentation with a serologic weak D phenotype (n = 26). RHD genotyping was performed using commercial and laboratory-developed tests. Of the 26 serologic weak D samples, 18 (69.2%) were found to carry alleles RHD*weak D type 1, 2, or 3. The remaining eight samples (30.8%) were found to carry partial D alleles. Of the 20 samples submitted because of D typing discrepancy, 7 (35%) carried alleles RHD*weak D type 1, 2, or 3, while 13 (65%) carried partial RHD alleles. This report summarizes the findings of one hospital system and its approach to integrating RHD genotyping into its assessment of risk of alloimmunization in obstetrics patients. It demonstrates that individuals with partial RHD alleles can present with serologic weak D phenotype, such that, without RHD genotyping, these individuals may not be identified as candidates for Rh immune globulin. The study also demonstrates that use of two methods (automated gel and tube testing) allows for identification of partial D cases that would otherwise be missed. I.</p>","PeriodicalId":13357,"journal":{"name":"Immunohematology","volume":"36 4","pages":"146-151"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25335056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of rare blood types in southern Brazil: impact on transfusion support.","authors":"Cristiane da Silva Rodrigues de Araújo,&nbsp;Bruna A Machado,&nbsp;Cristiana D Reche,&nbsp;Larissa Maroni,&nbsp;Luana C Garlet,&nbsp;Manuela Meinhardt Pinheiro Dos Santos,&nbsp;Marina Beber,&nbsp;Adriano Pasqualotti,&nbsp;Lilian Castilho","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Conclusions: </strong>The prevalence of blood group antigens and phenotypes varies significantly in Brazil. To ensure a proper rare blood supply, it is essential to establish a local and regional database of rare donors connected to the national registry. The objective of this study was to create a database of rare blood donors in the northern region of southern Brazil. From November 2011 to December 2018, red blood cell (RBC) phenotyping and genotyping were performed on common and high-prevalence antigens in donors and patients in southern Brazil. During this study period, 17 patients and 33 blood donors with rare phenotypes were identified. Six patients had already been alloimmunized to clinically significant antigens. Patients with the following phenotypes (i.e., negative for highprevalence antigens) were found: Yt(a-), Jk(a-b-), Lu(a-b-), Oh (Bombay), Tc(a-), k-, and Fy(a-b-). Among the donors, Kp(a+b-), Fy(a-b-), Lu(a-b-), and k- phenotypes were identified. We also found four donors with the weak D type 18 phenotype. In conclusion, we observed that the prevalence of rare blood phenotypes in our region corresponds more to the prevalence found in the Caucasian population when compared with other regions in Brazil. Our results show the importance of continuous screening for rare donors in different regions of the country and the creation of a local database to support RBC transfusions in patients who need rare blood.</p>","PeriodicalId":13357,"journal":{"name":"Immunohematology","volume":"36 4","pages":"152-156"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25335057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A resource-conserving serologic and highthroughput molecular approach to screen for blood donors with an IN:-5 phenotype.","authors":"Sanmukh R Joshi, Snehal B Senjaliya, Kshitij Srivastava, Willy A Flegel","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Conclusions: </strong>The Indian blood group system (ISBT 023) comprises one lowprevalence antigen, Ina (IN:1), and five high-prevalence antigens: Inb (IN:2), INFI (IN:3), INJA (IN:4), INRA (IN:5), and INSL (IN:6). The antigens are located on the single-pass trans-membrane glycoprotein encoded by the CD44 gene. The present study was designed to identify the prevalence of the INRA- (IN:-5) phenotype and the frequency of its associated allele (IN*02.- 05) to inform us of the probability of finding antigen-negative donors and to assess the risk of antibody formation in transfusion recipients. Buffy coats were extracted from EDTA-anticoagulated whole blood samples, collected with consent from 5261 random blood donors in Surat, Gujarat, India. Standard serologic methods were performed with a modification allowing the use of antiserum generated by recycling the antibody augmented from the test already performed. A real-time polymerase chain reaction- based assay was devised to genotype c.449G>A (p.Arg150His) single nucleotide variation in exon 5 of the CD44 gene. None of the 411 donors tested by serology or the 5261 donors tested molecularly were positive for the IN:-5 phenotype or the allele (IN*02.-05), respectively. The allele frequency estimate ranged from less than 1 in 10,522 (0.01%) to 1 in 3203 alleles (0.03%) in the study cohort (95% confidence interval, Poisson distribution). The absence of this rare allele in the present survey could be due to an ethnic difference, since the donors mostly came from the Hindu community, and the only case of the IN:-5 phenotype was found in the Muslim community. The p.150His variant may be either restricted to the index case family or only found in the Muslim community. Further studies in local subpopulations may provide more information on the frequency of p.150His and its immunogenicity in transfusion recipients if occurring among blood donors.</p>","PeriodicalId":13357,"journal":{"name":"Immunohematology","volume":"36 4","pages":"129-132"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870012/pdf/nihms-1658464.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25335053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ANNOTATION-Monoclonal ABO blood grouping reagents: a decade later.","authors":"M. Beck, J. Kirkegaard","doi":"10.21307/IMMUNOHEMATOLOGY-2019-791","DOIUrl":"https://doi.org/10.21307/IMMUNOHEMATOLOGY-2019-791","url":null,"abstract":"","PeriodicalId":13357,"journal":{"name":"Immunohematology","volume":"11 3 1","pages":"67-70"},"PeriodicalIF":0.0,"publicationDate":"2020-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43885524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}